Annual report

Highlights of 2010
_In 2010 Galenica generated consolidated net sales of CHF 3,104.3 million (+6.6% year-on-year). Despite increased investments in research and development and the marketing of Ferinject® as well as difficult market conditions, Galenica increased consolidated net profit by 10.8% to CHF 232.1 million. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased by 11.3% to CHF 444.9 million, while earnings before interest and taxes (EBIT) rose to CHF 324.8 million (+22.6%).

_With the launch of Ferinject® that is currently underway across Europe, the preparations for the registration of Injectafer® in the US and for PA21 worldwide, as well as with the creation of Vifor Fresenius Medical Care Renal Pharma Ltd., Galenica has embarked on an extremely important implementation phase. The Pharma business sector will continue to pursue its strategy.

_ On a like-for-like basis the sales of the Logistics business sector were higher than in the previous year and developed better than the market, which declined by 2%. The Retail business sector increased sales by 30.1% . Most of this growth came from the acquisition of Sun Store. The accelerated rollout of the latest version of the pharmacy software TriaPharm® had a positive impact on the sales and profit of HealthCare Information.